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ABSTRACT
The majority of oligodendrogliomas (ODGs) exhibit combined losses of 
chromosomes 1p and 19q and mutations of isocitrate dehydrogenase (IDH1-R132H 
or IDH2-R172K). Approximately 70% of ODGs with 1p19q co-deletions harbor somatic 
mutations in the Capicua Transcriptional Repressor (CIC) gene on chromosome 
19q13.2. Here we show that endogenous long (CIC-L) and short (CIC-S) CIC proteins 
are predominantly localized to the nucleus or cytoplasm, respectively. Cytoplasmic 
CIC-S is found in close proximity to the mitochondria. To study wild type and mutant 
CIC function and motivated by the paucity of 1p19q co-deleted ODG lines, we created 
HEK293 and HOG stable cell lines ectopically co-expressing CIC and IDH1. Non-mutant 
lines displayed increased clonogenicity, but cells co-expressing the mutant IDH1-
R132H with either CIC-S-R201W or -R1515H showed reduced clonogenicity in an 
additive manner, demonstrating cooperative effects in our assays. Expression of 
mutant CIC-R1515H increased cellular 2-Hydroxyglutarate (2HG) levels compared 
to wild type CIC in IDH1-R132H background. Levels of phosphorylated ATP-citrate 
Lyase (ACLY) were lower in cell lines expressing mutant CIC-S proteins compared to 
cells expressing wild type CIC-S, supporting a cytosolic citrate metabolism-related 
mechanism of reduced clonogenicity in our in vitro model systems. ACLY or phospho-
ACLY were similarly reduced in CIC-mutant 1p19q co-deleted oligodendroglioma 
patient samples.  
INTRODUCTION
Oligodendrogliomas (ODG)s are a histologically, 
therapeutically and cytogenetically distinct subgroup of 
gliomas [1]. The majority of ODGs exhibit combined loss 
of chromosomes 1p and 19q and recurrent mutations of 
IDH1 or IDH2 (R132H or R172K respectively) [2]. Such 
ODGs are slow growing, respond well to chemotherapy 
and patients exhibit improved survival outcome compared 
to other gliomas that retain 1p [3, 4]. DNA sequencing of 
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ODG tumour samples with 1p and 19q deletions identified 
somatic mutations in the gene CIC [2, 5] located on 
chromosome 19q13.2. CIC mutations affected 53-69% of 
ODG cases, and included missense, nonsense, and out-of-
frame insertions and deletions [2, 5–7]. More than 25% 
of the CIC mutations were predicted to inactivate their 
encoded proteins [5]. Such inactivating mutation patterns 
are generally observed in tumour suppressor genes such as 
TP53 and FBXW7, but not in oncogenes [5]. Among the 
somatic mutations observed in CIC, 41% and 7% of the 
missense mutations were found in the CIC DNA-binding 
HMG domain and the Groucho protein-protein interaction 
domain, respectively [2, 5, 7, 8]. 
Somatic mutations were also observed in the gene 
encoding far upstream element (FUSE) binding protein1 
(FUBP1) on chromosome 1p31.1 [5] at a frequency (16%) 
lower than CIC mutations. A recent study of 45 ODGs with 
1p19q co-deletions identified two hotspot point mutations 
(-124 and -146 bp upstream from the ATG start site) in 
the promoter region of telomerase reverse transcriptase 
(TERT) [9] on chromosome 5p15.33, the catalytic subunit 
of the enzyme telomerase. These point mutations create a 
binding sequence for the ETS transcription factor, which 
can subsequently activate TERT transcription. Exactly how 
these mutations contribute to oligodendrogliomagenesis 
has yet to be determined. 
CIC is well conserved across evolutionary 
boundaries [10, 11], and was first identified as a HMG-
box repressor downstream of the RTK-Ras–Raf–MAPK 
cascade [12] in Drosophila. In addition to terminal 
and dorsoventral patterning [12, 13] and wing vein 
specification [14], CIC is involved in ommatidial cell 
proliferation [15]. During ommatidial development, 
activation of EGFR signaling and down regulation of 
CIC levels was required for promoting cell growth and 
cell proliferation. At least two main CIC protein isoforms, 
which differ in both size (short form, CIC-S; long form, 
CIC-L) and in their N-terminal regions, have been 
identified in Drosophila and mammals. Both CIC-S and 
CIC-L are highly conserved between mouse and human 
(>99% amino acid identity) [10, 11], with predicted 
lengths of 1,608 AA and 2,517 AA respectively. 
Relatively few studies have addressed the role of 
CIC in human biology and disease. For example, CIC 
appears to repress the PEA3 family of ETS transcription 
factors in cancers. Rare cases of Ewing’s sarcoma express 
a novel CIC–DUX4 fusion protein encoded by a recurrent 
chromosomal translocation t(4;19)(q35;q13) [16]. This 
fusion protein activated transcription of the PEA3 family 
genes ERM/ETV5 and ETV1 and overexpression of 
PEA3 family proteins was associated with invasive and 
metastatic phenotypes in breast and gastric cancers and 
in rhabdomyosarcoma [17]. In HEK293 cells, ribosomal 
protein S6 kinase II (p90RSK) phosphorylated CIC and 
promoted the binding of phosphorylated CIC to 14-
3-3 regulatory proteins [18]. This interaction reduced 
the binding of CIC to CIC binding “TGAATGAA” 
promoter sequences and reduced CIC repressor activity. 
The reduced binding of CIC correlated with increased 
expression of CIC targets in vitro, such as ETV5 [18]. 
Finally, association of wild type CIC with polyglutamine-
expanded ATAXIN-1 results in neurotoxicity and 
contributes to spinocerebellar ataxia (SCA1) [10, 19]. 
An ATXN1-CIC protein complex showed enhanced 
transcriptional repressor activity compared to CIC 
alone [10] and reducing CIC levels rescued the Ataxia 
phenotype in mouse models period. Additional in vitro and 
in vivo studies in mammalian systems are now required to 
elucidate the cellular functions of both CIC mutant and 
wild type proteins. 
Alterations in glycolysis and citrate metabolism 
contribute to the survival of cancer cells including gliomas 
[20–22]. In cancers cells, the citrate transporter SLC25A1 
preferentially transports mitochondrial citrate produced by 
the TCA cycle to the cytosol, where citrate plays a central 
role in metabolism [23, 24]. Cytosolic citrate can be 
converted to oxaloacetate (OAA) and acetyl-CoA by the 
enzyme ATP-citrate lyase (ACLY) in an ATP dependent 
manner. Acetyl-CoA is required for de novo lipid synthesis 
and acetylation of histones in proliferating cancer cells [24, 
25]. Cytosolic citrate is also converted into isocitrate by 
acotinase and then into α-2-ketoglutarate (2KG) by IDH1 
[24]. However, mutant variants of IDH1 (eg.R132H/C/S/
L/G/V) exhibit a neomorphic function that converts 2KG 
to the oncometabolite (R)-2 hydroxyglutarate (2HG) [26, 
27]. Intracellular levels of 2HG are high in cancer cells 
containing IDH mutations and are sufficient to promote 
cell transformation [28]. In gliomas, 2HG significantly 
decreased 5-hydroxymethylcytosine (5hmC), increased 
DNA methylation and reduced DNA de-methylation, 
ultimately leading to a CpG island methylator phenotype 
(CIMP) [29]. 
In 1p19q co-deleted ODG, CIC mutations co-occur 
with mutations in either IDH1 or IDH2 in approximately 
53-69% of cases, but the functional consequences of 
this co-occurrence are unknown [2, 5–7]. Here we 
describe, for the first time, the sub-cellular localization 
of endogenous CIC isoforms in human cells, including 
ODG cells with 1p19q co-deletions. Endogenous 
CIC-L was predominantly localized to the nucleus. 
Endogenous CIC-S was predominantly cytoplasmic, in 
close proximity to mitochondria, and formed complexes 
with ACLY which synthesizes acetyl-CoA in the cytosol. 
We show that cells expressing mutant CIC proteins had 
lower levels of active phosphorylated ACLY (pACLY) 
compared to cells expressing wild type CIC. Cells co-
expressing mutant IDH1-R132H and mutant CIC-R1515H 
displayed increased 2HG levels compared to cells co-
expressing mutant IDH1-R132H and wild type CIC. Cells 
expressing IDH1-R132H mutations exhibited reduced cell 
proliferation compared to cells expressing wild type IDH1 
or cells co-expressing both wild type CIC and IDH1. 
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Co-expression of mutant IDH1-R132H and wild type 
CIC partially rescued the reduction in cell proliferation. 
Co-expression of mutant CIC (-R1515H and -R201W) 
and mutant IDH1-R132H further reduced clonogenicity 
compared to cells expressing mutant IDH1-R132H. Our 
data provide the first insights into the localization and 
function of mammalian wild type CIC and the mutant 
CIC proteins found in ODGs (eg. CIC-R1515H and CIC-
R201W) in wild type IDH1 and mutant IDH1-R132H 
backgrounds and allude to novel non-nuclear functions of 
CIC.
RESULTS
Capicua isoforms localize to different cellular 
compartments in mammalian cells
To further characterize the predominant endogenous 
CIC protein isoforms (CIC-L and CIC-S) in human cells 
[2], we prepared whole cell lysates of human embryonic 
kidney cell line HEK-293A: (hereafter referred to as HEK) 
and detected CIC proteins using western blotting. Our 
analysis of primary amino acid sequences predicted that 
CIC-S and CIC-L were 164 KDa and 259 KDa in size. 
However, an anti-CIC antibody (Methods) consistently 
detected two major protein bands that migrated at 
approximately 230 KDa and 400 KDa (Figure 1A; 
Supplementary Figure S1). We occasionally detected 
a smaller isoform at 170 KDa (Supplementary Figure 
S1) but did not study this minor isoform further due to 
its variable presence. To validate the CIC antibody, 
we knocked down CIC using three different siRNAs 
(Methods) and quantitated CIC proteins using western 
blots and densitometry. Compared to scramble siRNA 
controls, CIC-siRNA1 or CIC-siRNAs1+2+3 significantly 
reduced both 230 KDa CIC-S and 400 KDa CIC-L protein 
bands to approximately 15% and 45% of control levels 
respectively (Figure 1B). To confirm the migration of 
CIC-S and CIC-L at 230 KDa and 400 KDa on protein 
gels, we ectopically expressed N-terminally FLAG fused 
Figure 1: Subcellular localization of endogenous CIC isoforms in mammalian cells. A. Western blots using an anti-CIC 
antibody detected CIC isoforms CIC-L (400 KDa) and CIC-S (250 KDa) in HEK cells. B. HEK cells were transfected with a single siRNA 
(siRNA1) or a three siRNAs in combination (siRNA1+2+3) against CIC. Reductions in CIC-S and CIC-L were detected after 72hrs using 
western blots. Data are representative of three independent experiments. Changes in band intensities for CIC-L and CIC-S after siRNA1 
treatment relative to scramble siRNA were quantified using densitometry and averaged over three independent experiments to generate the 
bar graph. C. N-terminal FLAG fusions with CIC-S (F-CIC-S) and CIC-L (F-CIC-L) were ectopically expressed in HEK cells and detected 
using a FLAG antibody. D. Whole lysate preparations of gliomas (van-20: Glioblastoma, no IDH1 mutation, no 1p19q co-deletion; van-
42 and van 46: oligodendroglioma, IDH1_R132H mutation, 1p19q loss) were probed for endogenous CIC expression using an anti-CIC 
antibody. E. Subcellular fractionations of ODG cell lines BT054 and BT088 were performed and cytoplasmic (Cyto) and nuclear (Nuc) 
fractions were isolated. Endogenous CIC isoforms were detected using western blots. Data shown are representative of three independent 
experiments. CIC-S is enriched in cytoplasmic fractions and CIC-L is enriched in nuclear fractions. F. Cytoplasmic (Cyto) and nuclear 
(Nuc) fractions were isolated from HEK cells and endogenous CIC isoforms were isolated using immunoprecipitations (IPs) with an anti-
CIC antibody. Subcellular localization of the isoforms was detected using a different anti-CIC antibody (by western blot analysis). Tubulin 
(Cyto) and TATA binding protein (TBP; Nuc) were detected as control proteins. Data shown are representative of at least three independent 
experiments.
Oncotarget7963www.impactjournals.com/oncotarget
CIC-S (F-CIC-S) and CIC-L (F-CIC-L) proteins in HEK 
cells and detected CIC using a FLAG antibody and 
western blotting. F-CIC-S and F-CIC-L were detected 
at approximately 230 KDa and 400 KDa respectively 
(Figure 1C), confirming that CIC-S and CIC-L migrate at 
these molecular weights. We next explored whether these 
isoforms were present in gliomas. We isolated proteins 
from one non-ODG tumour with a 1p deletion, two ODG 
tumors with 1p19q co-deletions, and cultured ODG cells 
BT054 (IDH1+/R132H/CIC+/-) and BT088 (IDH1+/+/CICR1515H/-) 
[30], both containing 1p19q co-deletions. We detected 
the CIC-S isoform in all samples and the CIC-L isoform 
in two of three glioma tumor samples and in both ODG 
cell lines, indicating CIC isoforms of the expected size 
are present in glioma cells (Figure 1D-E, Supplementary 
Figure S1). 
To determine the subcellular localization of 
endogenous CIC-S and CIC-L isoforms in HEK cells, 
we fractionated cells, purified cytoplasmic and nuclear 
fractions, and detected proteins that were enriched in these 
fractions (Methods). To assess the distribution of CIC-S 
and CIC-L, we immunoprecipitated (IP) CIC proteins 
Figure 2: Mass spectrometry analysis confirms the localization of CIC-L to nuclei and CIC-S to the cytoplasm. A. 
Shown are the locations of the CIC peptides used to monitor the subcellular location of CIC by Multiple Reaction Monitoring (MRM) 
MS assays. A protein alignment cartoon shows the positions of the measured peptides specific for CIC-L (1L-7L; red) and the measured 
peptides common for both isoforms (2C-10C; green), see Supplementary Figure 2 for the sequence of the peptides. CIC-L and CIC-S 
specific regions are indicated in hatched and grey, respectively. Unfilled regions are common to both isoforms. B. Nuclear and cytoplasmic 
fractions were isolated from HEK cells and CIC isoforms were immunoprecipitated using an anti-CIC antibody. Immunoprecipitates were 
run on a protein gel and proteins were isolated from 14 different slices of the gel in the 80-500 KDa region. Isolated proteins were used to 
detect peptides specific to CIC isoforms by MRM-MS. Peptides from each slice were measured. The peptide ion densities for the peptides 
are shown as a heat map for nuclear and cytoplasmic fractions (summed areas of each peptide transition peak, as counts per second2 (cps2)). 
The data are representative of two independent trials.
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from cytoplasmic and nuclear fractions and analyzed the 
IP samples using western blots. In fractionated samples, 
CIC-S at 230 KDa and CIC-L at 400 KDa were enriched 
in the cytoplasmic (59+/5%) and nuclear fractions (89+/-
5%), respectively (Figure 1F). In ODG lines BT054 
and BT088, CIC-S and CIC-L were also predominantly 
observed in the cytoplasmic and nuclear fractions, 
respectively (Figure 1E). 
To confirm the subcellular localization of CIC 
isoforms, we designed Multiple Reaction Monitoring 
(MRM) mass spectrometry (MS) assays for 10 peptides 
common to both isoforms and 9 peptides unique to the 
CIC-L isoform only (Figure 2A, Supplementary Figure 
S2). CIC protein IPs from cytoplasmic and nuclear 
fractions were separated on Tris-Acetate gels, and CIC 
peptide levels were measured in 14 gel slices spanning 
the 80-500 KDa range (Methods). In the nuclear fraction, 
6/9 peptides unique to CIC-L and 7/10 peptides common 
to both isoforms were detected only at 400 KDa (Figure 
2B), suggesting these peptides originated from the CIC-L 
isoform. In the cytoplasmic fraction at 230 KDa, we 
detected 7/10 peptides common to both isoforms but 
no peptides unique to CIC-L were observed. These data 
are consistent with the notion that the peptides detected 
at 230 KDa in the cytoplasmic fraction originated from 
the CIC-S isoform (Figure 2C). Taken together, these 
results confirmed that the proteins we detected at 230 and 
400 KDa were indeed CIC proteins, and that CIC-S is 
predominantly localized to the cytoplasm, while CIC-L is 
predominantly localized to the nucleus.
Cytoplasmic CIC-S is localized to mitochondria
During terminal and dorsoventral patterning 
of Drosophila embryos, CIC acts as a transcriptional 
repressor [12], yet in our standard culture conditions 
(Methods), ~59% of CIC-S was found in the cytoplasm. 
This indicated to us the potential for CIC functions 
beyond transcriptional regulation. To further explore 
the localization of CIC-S, we detected cytoplasmic CIC 
using immunofluorescence (IF). We visualized CIC in 
HEK, MDA-MB-231 (breast carcinoma), C643 (thyroid 
carcinoma), H522 (lung carcinoma), and HeLa (ovarian 
carcinoma) cells using an anti-CIC antibody that can 
detect both CIC-S and CIC-L. Consistent with our nuclear 
and cytoplasmic fractionation studies, we observed 
CIC in both the nucleus and cytoplasm (Figure 3A). 
An unexpected observation was that cytoplasmic CIC 
signal was concentrated in puncta apparently close to 
mitochondria (representative images in Figure 3A). 
To determine whether CIC was localized to 
mitochondria, we examined subcellular fractions of 
HEK cells enriched for cytoplasmic organelles (includes 
mitochondria; hereafter referred to as the mitochondrial 
fraction) or non-organelle cytosolic material. Control 
proteins ATP5A (mitochondrial) and tubulin (cytosolic) 
were predominantly in the mitochondrial fraction and 
cytosolic fractions, respectively, as expected (Figure 
3B). The CIC-S form was consistently observed in both 
cytosolic and mitochondrial fractions (Figure 3B) and 
CIC-S was also detected in the mitochondrial (Figure 3C) 
fractions in other carcinoma cell lines. 
To explore the nature of the CIC-S association 
with mitochondria, we isolated the mitochondrial 
fraction from HEK cells and subjected it to increasing 
concentrations of Proteinase K (0-15 µg/ml) under 
isotonic conditions. Under these conditions, Proteinase 
K digests proteins exterior to the mitochondrial outer 
membrane. However, proteins embedded within the outer 
membrane and proteins located inside the membrane 
are protected from digestion. Mitochondrial proteins 
ATP5A (matrix), VDAC (embedded in the outer 
membrane), TOMM20 (translocase located outside of 
outer mitochondrial membrane) and RHAMM/HMMR, 
a protein loosely bound to mitochondria [31], served 
as controls. While mitochondrial proteins ATP5A and 
VDAC were protected from Proteinase K treatment 
at 15 µg/ml, CIC-S, TOMM20 and RHAMM proteins 
were not protected (Figure 3D), indicating that CIC-S 
was most likely localized outside the mitochondrial 
outer membrane. To confirm that CIC-S was located 
exterior to the outer membrane of mitochondria and not 
embedded in the outer membrane, we used carbonate to 
solubilize proteins that are not embedded in the outer or 
inner membrane of mitochondria [31]. We treated the 
mitochondrial fraction from HEK cells with carbonate 
buffer (Methods) and detected CIC-S using western blots. 
As shown in Figure 3E, CIC-S and matrix protein ATP5A 
solubilized in the carbonate buffer and VDAC remained in 
the pellet containing mitochondrial membrane. Our result 
indicates that CIC is not embedded in the mitochondrial 
membrane but may instead be loosely associated with 
the mitochondrial membrane (Figure 3E). These findings 
are consistent with the notion that in mammalian cells, 
endogenous CIC-S is located very near or perhaps on the 
surface of mitochondria.
We next sought to determine the subcellular 
localization of both wild type and mutant endogenous CIC 
in ODG cell lines (BT054 and BT088) that carried 1p19q 
co-deletions in different IDH1 genetic backgrounds. While 
BT054 carries mutant IDH1 (R132H) and wild type CIC 
alleles, BT088 lacks mutant IDH1 but carries a mutant 
CIC allele, encoding R1515H in the protein–protein 
interaction domain, and no wild type CIC allele [2, 30]. 
We performed immunofluorescence (IF) experiments 
using an anti-CIC antibody that recognized both wild 
type and mutant CIC and an antibody that recognizes the 
mitochondrial protein ATAD3A [32]. Cytoplasmic CIC 
appeared to be adjacent to mitochondria in both BT054 
and BT088 ODG cell lines (Figure 4A). 
To determine whether wild type and mutant CIC-S 
were detected in the mitochondrial fraction in ODG cells, 
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we isolated cytosolic and mitochondrial fractions of 
both BT054 and BT088 and detected CIC using western 
blots. In both ODG cell lines, CIC-S was detected in 
both cytosolic and mitochondrial fractions (Figure 4B). 
Compared to wild type CIC in BT054, levels of CIC-
R1515H in BT088 were observed at higher levels in both 
fractions, indicating CIC-R1515H is stable and that the 
mutation did not affect subcellular distribution between 
cytosolic and mitochondrial fractions. 
Expressions of both CIC and IDH mutant 
cooperatively increased 2HG production in 
HEK293 cells
In our previous study [2], 69% of ODGs with 1p19q 
co-deletions carried mutations in both the IDH and CIC 
genes. Since mutations in IDH1 and IDH2 increase the 
production of 2HG [26] and endogenous CIC-S was 
observed close to mitochondria, we hypothesized that 
Figure 3: CIC-S is in close proximity to mitochondria and present in both cytosolic and mitochondrial fractions. A. 
To further study the subcellular localization of CIC, an immunofluorescence assay was performed using an anti-CIC antibody (green). 
Mitochondria were visualized using either Mitotracker red or an anti-ATP5A antibody (red). The nucleus was visualized using DRAQ5 
stain (blue). HEK, MDA-MB-231 (breast carcinoma) and C643 (thyroid carcinoma) cells were observed using a confocal microscope. 
Boxes in the merge column indicate the zoomed area. Arrows in magnified images (labeled Zoom) show CIC-positive-puncta localizing 
along mitochondria. B. HEK cytosolic (Cytos) and mitochondrial (Mito) fractions were further isolated from cytoplasmic fractions and 
CIC-S was detected using western blots. To validate the fractionation method, control proteins tubulin (cytos) and ATP5A (mito) were 
also detected. CIC-S is enriched in the cytosolic and mitochondrial fractions. Mitochondrial fractions were isolated from human cancer 
cell lines HeLa (ovarian), MDA-MB-231 (breast) and H522 (lung) and CIC-S was detected using an anti-CIC antibody and western 
blots. Control proteins ATP5A and VDAC (mitochondrial) were detected. CIC-S was found in mitochondrial fractions in all cells. C. The 
mitochondrial fraction was isolated from HEK cells and a Proteinase K protection assay was performed using 0-15µg/ml Proteinase K 
(ProtK). CIC-S protein was detected following treatment with Proteinase K. Control proteins VDAC (embedded in the mitochondrial outer 
membrane), ATP5A (mitochondrial matrix), TOMM20 (translocase of outer mitochondrial membrane), and HMMR (loosely associated 
with the outer mitochondria membrane) are also shown. ATP5A and VDAC but not CIC-S, TOMM20 and HMMR were protected at 15µg/
ml ProtK indicating that CIC-S is localized outside mitochondria. Results shown are representative of three independent experiments. 
D. Mitochondrial fractions from HEK cells were treated with carbonate buffer and centrifuged to pellet (P) proteins embedded in the 
mitochondrial membrane fraction. The supernatant (S) contained proteins located in the inner membrane space, matrix and the proteins 
loosely bound to mitochondrial outer membrane. CIC-S was detected in the supernatant suggesting it is not embedded in the mitochondrial 
membrane. The result shown is representative of three experimental replicates.
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mutations in IDH and CIC-S might coordinately promote 
the production of 2HG. To test this hypothesis, we derived 
stable HEK cell lines that ectopically expressed wild 
type CIC-S or mutant CIC-S (both R1515H and R201W) 
fused to N-terminal FLAG (hereafter referred to as F-CIC 
or F-CIC-R1515H or F-CIC-R201W), in combination 
with wild type IDH1 (hereafter referred to as IDH1-V5) 
or mutant IDH1-R132H (hereafter referred to as IDH1-
R132H-V5) fused to C-terminal V5 proteins (Figure 5A). 
We are aware of only two available 1p19q co-deleted ODG 
cell lines, described above. Both lines grow very slowly 
and are resistant to transfection. Hence, we developed and 
used stably transformed HEK cells, as such cells were 
reported to exhibit properties similar to those of immature 
neurons [33]. To confirm previous reports [26, 29] in 
which cells expressing IDH1-R132H-V5 exhibited higher 
levels of 2HG compared to cell lines expressing wild type 
IDH1, we first quantified the levels of total 2HG (our 
assay measures both L-2-HG and D-2-HG) in our stable 
lines using MRM-MS. Our stable lines expressing IDH1-
R132H-V5 showed low-moderate levels of 2HG in early 
passages and stabilized after passage #8, after which point 
they expressed approximately >15 fold 2HG compared to 
a stable line expressing IDH1-V5 (Supplementary Figure 
S3A). Subsequent experiments detecting 2HG were thus 
performed with cells after passage #8. 
Next, we used MRM-MS to measure the levels 
of 2HG and 2KG in lines stably transfected with wild 
type and mutant expressing IDH and CIC constructs. 
Comparison of cells expressing mutant IDH1-R132H-V5 
to cells expressing wild type IDH1 showed significant 
increases in 2HG (p<0.0001; Figure 5B). There were no 
significant differences in total 2HG levels between cells 
expressing wild type IDH1 alone or cells co-expressing 
wild type IDH1 with wild type F-CIC, F-CIC-R1515H, 
or F-CIC-R201W (Figure 5C). Cells expressing IDH1-
R132H-V5 alone and cells co-expressing IDH1-
R132H-V5/F-CIC, IDH1-R132H-V5/F-CIC-201W, or 
IDH1-R132H-V5/F-CIC-R1515H showed significant 
increases in 2HG levels (p<0.0001; p=0.0032, p<0.0001, 
respectively; Figure 5C). However, compared to cells co-
expressing IDH1-R132H-V5/F-CIC, cells co-expressing 
IDH1-R132H-V5/F-CIC-R1515H further showed a 
significant increase in 2HG levels (p<0.0001; Figure 
5C). In the IDH1-R132H-V5 background, the most 
significant increase in 2KG levels were observed in cells 
co-expressing F-CIC-R201W (p<0.0001; Figure 5C). 
To assess whether our observations were specific 
to our HEK-derived lines, we derived stable HOG cell 
lines that ectopically expressed wild type CIC-S or 
mutant CIC-S (R1515H or R201W), in combination with 
wild type IDH1 or mutant IDH1-R132H. The HOG cell 
line was derived from a human glioma and expresses 
oligodendrocyte-specific proteins [34]. This cell line 
Figure 4: CIC-S localizes to mitochondria in 1p19q co-deleted oligodendroglioma cell lines. A. Subcellular localization 
of CIC in ODG cell lines BT088 and BT054 was detected using immunofluorescence. CIC was detected using an anti-CIC antibody and 
mitochondria were stained using an anti-ATAD3A antibody. Cells were visualized using confocal fluorescence microscopy. B. Cytosolic 
(Cytos) and mitochondrial (Mito) fractions of BT054 and BT088 were isolated and CIC-S was detected using western blots. Control 
proteins ATP5A (Mito) and Tubulin (Cytos) were also detected.
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Figure 5: IDH1-R132H and mutant CIC coordinately regulate 2HG production in vitro. A. Stable cell lines expressing either 
wild type IDH1-V5 or mutant IDH1-R132H-V5 in combination with wild type F-CIC or mutant F-CIC-R1515H or F-CIC-R201W were 
established and proteins detected using western blots. Expression of CIC and mutant IDH1-R132H were detected using antibodies specific 
to CIC or IDH1-R132H proteins. Mutant and wild type IDH1 proteins were fused to a V5 epitope and detected using an anti-V5 antibody. 
B. Levels of total cellular 2HG from HEK-derived stable cells (passage #11-14) expressing wild type IDH1-V5 or IDH1-R132H-V5 were 
detected using targeted MRM-mass spectrometry. The values reported are averaged peak areas for 2HG that were normalized to the total 
area within each biological replicate. Error bars represent the SD from 3 independent biological replicates and 3 technical replicates of each 
(3 MS runs of the same sample), for a total of 9 data points for each experiment. C. Levels of 2HG or 2KG were detected using targeted 
MRM-mass spectrometry from HEK-derived cells co-expressing wild type or mutant CIC with wild type or mutant IDH1 (passage #11-14). 
The values reported are averaged peak areas for 2HG or 2KG that were normalized to the total area within each biological replicate. Error 
bars represent the SD from 3 independent biological replicates and 3 technical replicates, for a total of 9 data points per experiment. Note 
the different scales of the Y-axes in the 2HG graphs. D. Levels of 2HG were detected using an enzymatic assay [37] from HOG-derived cells 
co-expressing wild type or mutant CIC with wild type or mutant IDH1 (passage #10-13). 2HG levels (µM) were calculated from standard 
curves established using D-2-Hydroxyglutaric acid. The averaged values reported were derived from four biological replicates. Note the 
different scales of the Y axes in the 2HG graphs. E. A model depicting the cooperative regulation of 2HG in cells co-expressing mutant 
IDH1-R132H and mutant CIC-R1515H/-201W. When high levels of citrate are produced in the mitochondria, citrate is shuttled to the 
cytosol. Cytosolic citrate may have two fates in cancer cells. (1) In actively proliferating cells, citrate is used by ACLY to produce Acetyl-
CoA in an ATP dependent manner. Acetyl-CoA is used for de novo lipid synthesis. (2) Citrate is used to produce 2-alpha ketoglutarate 
(2KG) by IDH1. Mutant IDH1_R132H converts 2KG into 2-alpha-hydroxyglutarate (2HG). CIC is in close proximity to mitochondria and 
appears to play a role in diverting citrate towards 2HG production.
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Table1: The candidate mitochondrial and metabolism related interaction partners of CIC. Columns 1 and 2 
indicate UniProt protein name and accession number. Column 3 indicates the gene name, synonym and function. A total of six 
immunoprecipitation experiments (IP), 4 IP experiments with an endogenous antibody (E-1, E-2, E-3, W-1), and 3 experiments 
with a Myc (M-1) or GFP (G-1) or FLAG (F-1) antibody of N-terminus CIC fusion proteins (MYC-CIC, GFP-CIC and FLAG-
CIC, respectively) were conducted in HEK cells. Candidate proteins shown here were those observed in at least two independent 
IP experiments and not observed in the control IPs (4 IgG, and one each of FLAG, MYC or GFP empty vector) that were 
mitochondrial, or had metabolism related functions. Column 4 indicates the IP method for each candidate interaction partner. 
Column 5 indicates the Mascot score observed for each protein. Column 6 indicates the number of discrete (unique) peptides 
observed in the IP experiments. 
UniProt Protein identification information






ACLY P53396 ATP-citrate synthase; ACLY; E-1 135 3
(ATP citrate-lyase) E-2 388 9
E-3 224 7
Mitochondrial
ADT2 P05141 ADP/ATP translocase 2; SLC25A5; ANT2 E-2 104 2
(exchange of cytoplasmic ADP with 
mitochondrial ATP) G-1 392 8
ATD3A Q9NVI7 ATPase family AAA domain-containing protein 3A; ATAD3A E-2 349 8
(mitochondrial network organization, 
mitochondrial DNA replication) E-3 197 5
ATPA P25705 ATP synthase subunit alpha, mitochondrial: ATP5A1; ATP5A M-1 104 3
(alpha subunit  of F1-ATPase catalytic 
core) G-1 96 3
ATPB P06576 ATP synthase subunit beta, mitochondrial; ATP5B; E-2 105 2
(beta subunit  of F1-ATPase catalytic 
core) G-1 87 2
DHX30 Q7L2E3 Putative ATP-dependent RNA helicase DHX30; DHX30; DDX30 E-1 142 5
(Associates with mitochondrial DNA) E-2 64 2
E-3 93 3
M-1 584 12
DNM1L O00429 Dynamin-1-like protein; DNM1L; DLP1 E-1 380 8
(mitochondrial and peroxisomal 
division) E-2 110 3
W-1 374 10
EFTU P49411 Elongation factor Tu, mitochondrial; TUFM; E-2 184 3
(mitochondrial protein sysnthesis) G-1 206 4
GRP75 P38646 Stress-70 protein, mitochondrial; HSPA9; F-1 1214 22
(chaperone) G-1 430 8
HMMR O75330 Hyaluronan mediated motility receptor; HMMR; RHAMM E-1 38 1
(cell motility) E-2 904 20
W-1 151 4
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was previously determined not to harbour 1p19q co-
deletions or mutations in the IDH1 or IDH2 genes [35, 
36]. We determined 2HG levels in our stably transfected 
HOG cell lines using an enzymatic assay that is based 
on the detection of stoichiometrically generated NADH 
that was generated during the conversion of 2HG to 2KG 
in the presence of the enzyme (D)-2-hydroxyglutarate 
dehydrogenase (HGDH) and nicotinamide adenine 
dinucleotide (NAD+) [37]. In agreement with our HEK 
stable cell lines, comparison of cells co-expressing IDH1-
R132H-V5 and F-CIC to cells co-expressing IDH1-
R132H-V5 and F-CIC-R1515H showed a striking increase 
in 2HG levels (p<0.014; Figure 5D). Similar to our HEK 
cells, comparison of cells co-expressing IDH1-R132H-V5 
and F-CIC to cells co-expressing IDH1-R132H-V5 and 
F-CIC-R201W did not show an increase in 2HG levels 
(p=0.79; Figure 5D). In contrast to the HEK-derived 
stable line, the HOG stable line expressing IDH1-
R132H-V5 alone produced high levels of 2HG. However, 
co-expression of wild type F-CIC in combination with 
mutant IDH1-R132H significantly reduced the 2HG levels 
(p<0.003), indicating that CIC expression can modulate 
2HG production. Taken together, our results indicate that 
expression of mutant CIC-R1515H, but not wild type CIC 
or CIC-R201W, can cooperate with mutant IDH1-R132H 
to increase cellular levels of 2HG (Figure 5E). 
Examining the expression levels of F-CIC, F-CIC-
R1515H, and F-CIC-R201W over passages (passage 
#2-15) in HEK-derived stable cells lines showed 
gradually decreasing levels of F-CIC, but both mutant 
F-CIC-R1515H and F-CIC-R201W proteins were stable 
(Supplementary Figure S3B). Although all the HEK-
derived stable cell lines expressed similar levels of IDH1-
R132H in early passages (passage #2-4), the stable line 
expressing mutant F-CIC-R1515H showed the highest 
level of IDH1-R132H-V5 protein in late passages 
(Supplementary Figure S3C). Similarly, the HOG-derived 
stable cell line expressing mutant F-CIC-R1515H showed 
the highest level of IDH1-R132H-V5 protein in later 
passages (Supplementary Figure S3D), which may explain 
the significant increase in 2HG levels in these lines. 
CIC interacts with metabolism and mitochondrial 
related proteins 
To further shed insight into CIC function, we sought 
to identify CIC interacting proteins in the cytoplasm. We 
performed three co-immunoprecipitations (Co-IP) of 
cytoplasmic fractions using an anti-CIC antibody and 
rabbit IgG IPs as controls. We also transiently expressed 
CIC-S proteins with N-terminal FLAG, Myc or GFP tags 
in HEK cells, extracted the cytoplasmic fractions and 
performed IPs using anti-FLAG, anti-Myc or anti-GFP 
antibodies. Cells transfected with empty FLAG, Myc or 
GFP vectors served as controls. Isolated protein complexes 
were characterized using liquid chromatography and 
tandem mass spectrometry (LC-MS/MS). Consistent 
with a previous report showing interaction of CIC with 
Ataxin family members [10], we detected Ataxin2L in 
our IP experiments (Table 1). We also identified ACLY, a 
metabolism-related protein and 11 mitochondrial proteins 
as high-confidence candidate interaction partners of CIC 
in our LC-MS/MS experiments (Table 1). 
Since ACLY is involved in cytosolic citrate 
metabolism and alterations in citrate metabolism are 
important in malignancies [24], we chose to further 
study the ACLY/CIC interaction. Because the ACLY/CIC 
interaction was observed in endogenous IP experiments 
(Table 1, Figure 6A), we confirmed the interaction using a 
reciprocal IP strategy. We used an anti-ACLY antibody and 
western blots to detect CIC-S in the IP derived from a HEK 
cytoplasmic fraction (Figure 6A). We also co-expressed 
F-CIC and ACLY fused to a C-terminal V5 epitope 
(ACLY-V5) in HEK293 cells. CIC immunoprecipitation 
using anti-FLAG antibody also captured ACLY; however, 
IP with anti-FLAG in the absence of F-CIC failed to 
immunoprecipitate ACLY (Figure 6B), compatible with 
the notion that CIC-S forms complexes with ACLY. 
MMAB Q96EY8




(adenosylcobalamin biosynthesis) E-3 200 5
PTCD3 Q96EY7
Pentatricopeptide repeat-containing 
protein 3, mitochondrial; PTCD3; 
MRPS39
E-1 291 6
(Mitochondrial RNA-binding protein) E-2 64 1
M-1 41 1
Other




Mutations in CIC lead to reduced pACLY 
Phosphorylation of ACLY, including at Serine 454 
(hereafter referred to as pACLY), contributes to increased 
ACLY stability and activity [38–40]. ACLY converts 
cytosolic citrate to acetyl CoA, which promotes cancer 
cell proliferation [40, 41]. IDH1 converts cytosolic 
isocitrate, derived from citrate, into alpha-ketoglutarate 
(2KG). Mutant IDH1-R132H further diverts this pathway 
towards the production of the oncometabolite 2HG (Figure 
5D). These two pathways may thus compete for citrate. 
Having observed that CIC interacts with ACLY (Table 1, 
Figure 6A), we sought to determine the levels of ACLY or 
pACLY in cells expressing wild type or mutant CIC. The 
HEK-derived stable cell lines grown in DMEM+10%FBS 
did not show differences in growth or morphology. In 
contrast, when grown in serum free media with growth 
factors (ODG culturing media; see Methods), cells 
expressing mutant CIC formed reduced numbers of clones 
compared to cells expressing wild type CIC (Figure 6B). 
We measured the levels of total ACLY and pACLY after 
exposing our HEK stable cell lines to serum free media 
with or without growth factors for 6 hrs. Compared to 
cells expressing wild type CIC, we saw pACLY reductions 
in cells expressing either of the mutant CIC protein 
Figure 6: pACLY levels were low in cells expressing mutant CIC proteins. A. Immunoprecipitations with an anti-CIC antibody 
or rabbit IgG using cytosolic (nucleus-free and mitochondria-free) HEK cell fractions were performed and ACLY was detected using an 
anti-ACLY antibody. A reciprocal immunoprecipitation using an anti-ACLY antibody or rabbit-IgG and the cytosolic fraction of HEK cells 
was also performed and CIC-S was detected using an anti-CIC antibody and western blot analyses. Lanes 1 and 5 are input lysates for IP with 
ACLY antibody and IgG respectively. Two aliquots of IP with anti-ACLY were loaded onto Lanes 2 and 4. A control IP with IgG is shown in 
lane 3. The figures are representative of three experimental replicates. B. FLAG-tagged CIC (bait protein) and V5 tagged ACLY (prey) were 
co-expressed in HEK293 cells. Co-immunoprecipitation was carried out using anti-FLAG antibody. CIC and ACLY were detected using 
anti-FLAG and anti-V5 antibodies respectively and western blot analysis. ACLY was detected only in the presence of FLAG-CIC (lane1) 
and although it was expressed, not detected in the absence of the FLAG-CIC (lane 3), thus confirming that CIC interacts with ACLY in these 
cells. C. Stable cell lines expressing vector, F-CIC, F-CIC-R1515H or F-CIC-R201W were exposed to serum free media containing growth 
factors. Proliferating cell colonies were observed two weeks after culturing using crystal violet stain. To generate proliferation indices, 
crystal violet stain retained in the clones was re-suspended in 10% acetic acid and measured at A590. Proliferation indices were calculated 
relative to cells expressing vector only (endogenous CIC). Standard deviation (SD) values shown are from 3 independent experiments. 
D. Stable cell lines expressing F-CIC or F-CIC-R1515H or F-CIC-R201W were exposed to serum free media with or without growth 
factors (+GF or –GF respectively) for 6 hrs. Levels of total ACLY and phosphorylated ACLY (pACLY) were determined using western 
blot analysis. Densitometry quantitations of pACLY/tubulin for stable cell lines expressing F-CIC or F-CIC-R1515H or F-CIC-R201W 
with growth factors relative to F-CIC expression are shown. SDs were calculated from three independent experiments. P-values shown 
were calculated using Student’s t-test. E. HEK293 cells were transiently transfected with vector, F-CIC, F-CIC-R1515H or F-CIC-R201W. 
Cells were exposed to serum free media with growth factors (+GF) for 48 hrs after transfections. Levels of total ACLY and pACLY were 
determined using western blot analysis. Densitometry quantitations of pACLY/tubulin for stable cell lines expressing F-CIC or F-CIC-
R1515H or F-CIC-R201W relative to F-CIC expression are shown. SDs were calculated from three independent experiments. P-values 
shown were calculated using Student’s t-test.
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constructs but the most extreme reduction of pACLY was 
observed in cells ectopically expressing F-CIC-R1515H 
(p<0.0005) (Figure 6C). To confirm this observation, we 
transiently transfected wild type and mutant CIC proteins 
and measured the levels of ACLY and pACLY. Similar to 
the stable cell lines, cells transiently transfected with both 
F-CIC-R1515H and F-CIC-R201W showed reductions in 
pACLY (p<0.015 and p<0.016 respectively) compared to 
the wild type CIC (Figure 6E) supporting the notion that 
CIC mutations affect pACLY levels. 
We next investigated whether IDH1 and CIC 
mutations could affect ACLY or pACLY levels. We used 
our HEK and HOG-derived stable cell lines expressing 
mutant CIC in wild type or mutant IDH1 backgrounds. 
Figure 7: Cells expressing mutantCIC proteins exhibit reductions in pACLY. A. Western blot analyses were used to detect 
total ACLY and pACLY in HEK-derived cells grown for 48hrs in serum free culturing conditions with 0.5% FBS and growth factors. 
Densitometry quantitations of pACLY/tubulin and ACLY/tubulin levels with standard deviations (SD) are shown below the western blots. 
Relative protein levels of pACLY and ACLY in cells expressing mutant CIC proteins (F-CIC-R1515H, or F-CIC-R201W) were derived 
relative to control cells expressing vector only. As shown in the bar graph, independent of IDH mutational status, CIC-R1515H mutation 
resulted in significant reduction in pACLY (p<0.01). The p-value was calculated from three independent experiments using one-way 
ANOVA analysis. B. Total ACLY and pACLY were also detected in independent HOG-derived stable cell lines grown for 72hrs in serum 
free culturing conditions with 0.5% FBS and growth factors. Similar to HEK-derived stable cells, independent of IDH mutational status, 
the highest level of reduction in pACLY was observed in cells expressing mutant CIC (-R1515H). C. Cytosolic and mitochondrial fractions 
were isolated from ODG cells BT054 (IDH1+/R132H; CIC+/-) and BT088 (IDH1+; CICR1515H/-) and total ACLY and pACLY were detected in 
both cytosolic (Cytos) and Mitochondrial (Mito) fractions. The images shown are representative of 3 independent experiments. D. The 
levels of ACLY and pACLY in 1p19q co-deleted ODG tumours with known CIC and IDH1 status (n=10) were determined using western 
blot analysis. Densitometry quantitations of pACLY/tubulin and ACLY/tubulin levels were determined and are shown below the western 
blots. Tumours with wild type CIC (n=5) showed elevated levels of either ACLY or pACLY compared to the tumours with mutant CIC 
proteins (n=5). The most striking reduction in ACLY and pACLY was observed in a tumour sample with a truncated CIC protein (P79X). 
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In HEK stable lines, we saw significant differences in 
the levels of pACLY in cells expressing F-CIC-R1515H 
compared to F-CIC on both IDH1-V5 (p<0.004) and 
IDH1-R132H-V5 (p<0.02) backgrounds (Figure 7A). 
Cells expressing F-CIC-R201W compared to F-CIC also 
showed significant differences in the levels of pACLY on 
IDH1-R132H-V5 backgrounds (p<0.02; Figure 7A). We 
saw significant differences in the levels of total ACLY in 
cells expressing either F-CIC-R1515H or F-CIC-R201W 
compared to F-CIC in IDH1-R132H-V5 backgrounds 
(p<0.02 and p<0.001 respectively; Figure 7A). In HOG 
stable lines, we also saw reduced levels of pACLY in 
cells co-expressing mutant IDH1-R132H-V5 and mutant 
F-CIC-R1515H or F-CIC–R201W compared to wild type 
F-CIC (p<0.014 and p<0.02 respectively; Figure 7B).
We next assessed pACLY levels in ODG cell 
lines with wild type CIC (BT054; IDH1+/R132H/CIC+/-) 
and mutant CIC-R1515H (BT088; IDH1+/+/CICR1515H/-). 
In agreement with the results we obtained using our 
stably transfected cell lines, reduced pACLY levels were 
observed in BT088 cells compared to BT054 cells, both 
in the cytoplasmic and mitochondrial fractions (Figure 
7C). We next measured ACLY and pACLY levels in 
1p19q co-deleted oligodendroglioma patient samples with 
known CIC and IDH1 status. In agreement with our in 
vitro findings, tumours with wild type CIC (n=5) showed 
elevated levels of either ACLY or pACLY compared to 
tumours with mutant CIC proteins (n=5; Figure 7D). 
Strikingly, a tumour sample with a truncated CIC protein 
(P79X) showed dramatic reductions in ACLY and pACLY. 
We interpret these findings to indicate that wild type CIC 
forms protein complexes with ACLY, and CIC mutants act 
to reduce the levels of pACLY and/or ACLY. As depicted 
in Figure 5C and D, reduction in ACLY/pACLY levels 
in our cells and in 1p19q co-deleted tumours expressing 
mutant CIC is consistent with the notion that mutations 
in CIC facilitate the diversion of citrate towards the 
production of 2HG. 
Mutations in CIC and IDH1 cooperate to reduce 
proliferation and clonogenicity
Since pACLY levels were reduced and 2HG levels 
were increased in cells expressing CIC-R1515H and IDH1-
R132H, we predicted that mutant CIC, in cooperation 
with mutant IDH1, may alter cell proliferation, survival 
or death. To compare the proliferation of cells carrying 
F-CIC-R1515H or F-CIC-R201W and IDH1-R132H-V5 
to cells expressing wild type F-CIC with IDH1-V5, we 
performed clonogenic assays combined with crystal violet 
proliferative assays (hereafter referred to as crystal violet 
assays) under serum free conditions supplemented with 
0.5% Fetal Bovine serum (FBS) and growth factors. 
Without 0.5% FBS, both HEK and HOG cells do not 
adhere and form spheres; however, with 0.5% FBS, HEK 
and HOG cells can adhere and proliferate. In HEK stable 
cells, ectopic co-expression of F-CIC with IDH1-V5 
showed a 33% relative increase in proliferation compared 
to cells ectopically expressing IDH1-V5 alone (p<0.005; 
Figure 8A). Expression of IDH1-R132H-V5 alone 
decreased the relative proliferation of cells (44%+/-12; 
p<0.001) compared to IDH1-V5. Ectopic co-expression 
of F-CIC with IDH1-R132H-V5 partially rescued this 
low proliferative phenotype (Figure 8A). These findings 
suggest that CIC and IDH1 can cooperate to influence cell 
proliferation in vitro. Cells expressing mutant CIC proteins 
R1515H or R201W in a wild type IDH1 background 
showed significant decreases in relative cell proliferation 
compared to F-CIC with IDH1-V5 co-expression 
(reduced by 97% and 119% respectively; p<0.0001 for 
both). Compared to cells expressing IDH1-R132H-V5 or 
F-CIC-1515H alone, cells co-expressing IDH1-R132H-
V5/F-CIC-1515H showed further reductions (36% and 
28% respectively) in relative cell proliferation (Figure 
8A). Similarly, in HOG-derived stable lines, expression of 
IDH1-R132H-V5 alone decreased the relative proliferation 
of cells (43+/-7%; p<0.001) compared to IDH1-V5; 
ectopic co-expression of F-CIC with IDH1-R132H-V5 
partially rescued the low proliferative phenotype (Figure 
8A). Compared to cells expressing IDH1-R132H-V5, 
cells co-expressing IDH1-R132H-V5 and F-CIC-1515H 
or IDH1-R132H-V5 and F-CIC-201W showed further 
reductions (13 and 14% respectively) in relative cell 
proliferation (Figure 8A). Similar observations were also 
found in media without FBS in both HEK293 and HOG-
derived stable cell lines (Figure 8B). Cells co-expressing 
wild type CIC and mutant IDH1 formed numerous spheres 
that were also larger in size compared to cells expressing 
mutant IDH1 and either mutant CIC (-R1515H/-R201W) 
proteins (Figure 8B). These findings are in agreement 
with the notion that mutations in IDH1 and CIC are co-
operatively regulating cell clonogenicity. Although cells 
expressing IDH1-R132H-V5 and F-CIC-R1515H or 
IDH1-R132H-V5 and F-CIC-R201W exhibited dead cells 
after one week, we did observe survival of a small fraction 
of cells that continued to thrive.
In stable HEK cells expressing mutant F-CIC-
R1515H, we observed cells displaying anoikis after 
48 hours in culture. To assess whether these cells were 
undergoing caspase dependent cell death, we measured the 
activity of caspases 3/7 and the levels of cleaved PARP 
(product of caspases 3 and 7 activity) in our CIC wild 
type/mutant HEK-derived stable lines in combination 
with IDH1-R132H-V5. Cells expressing F-CIC-R1515H 
in either the IDH1-V5 or IDH1-R132H-V5 background 
showed significant increases (Figure 8C; p<0.0001) in 
caspase activity and yielded higher levels of cleaved 
PARP compared to vector only, wild type CIC and CIC-
R201W (Figure 8D). Reduction in ACLY and pACLY 
elicited cell death in non-small cell lung cancer cells 
[42] and pancreatic beta cells [43], and so we sought 
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Figure 8: CIC and IDH1 coordinately regulate cell clonogenicity and mutations in CIC regulate cell death by reducing 
pACLY levels in vitro. A. Clonogenic assays of HOG and HEK-derived stable cell lines were performed in serum free media with 
low FBS and growth factors. Proliferating cell colonies were visualized using crystal violet stain one week (HOG) or two weeks (HEK) 
after culturing. Proliferation indices were calculated relative to cells expressing IDH1-V5 and vector only (endogenous CIC). Error bars 
represent the SD from 3 independent experiments. Multiple comparisons using mean values were performed using one-way ANOVA. B. 
Stable cell lines were cultured under oligodendroglioma cell growing conditions without FBS to form spheres. Spheres were viewed under 
an inverted light microscope. Images were taken 1 week after plating. Compared to cells expressing wild type IDH1 only or wild type IDH1 
and CIC, sphere formation was reduced in cells expressing mutant CIC and mutant IDH1. Sphere counts (+/- standard deviation) represent 
results obtained from 3 independent experiments. C. Stable cell lines were grown in serum free media with 0.5% FBS and growth factors 
for 72hrs and caspase 3 and 7 expression was determined using the Caspase-Glo® 3/7 assay. Caspase levels were calculated relative to 
cells expressing IDH1-V5 and vector only (endogenous CIC). Cells expressing F-CIC-1515H showed the highest levels of caspase activity 
(p<0.0001). Error bars represent the SD from 3 independent experiments. D. Stable lines expressing mutant IDH1-R132H-V5 combined 
with wild type F-CIC or mutant F-CIC-R1515H or F-CIC-R201W were cultured for 48hrs with or without 10µM zVAD (a pan caspase 
inhibitor) to determine whether reduction in pACLY led to cell death. Levels of total ACLY, pACLY and cleaved PARP were detected using 
western blots. zVAD treatment significantly reduced cleaved PARP in cells expressing mutant CIC. Western blots are representative of 3 
biological replicates and the bar graphs shown are densitometry quantitations from 3 biological replicates.
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to confirm this in our model system. To inhibit caspase 
activity, we treated cells with a pan caspase inhibitor 
Z-VAD-FMK (zVAD). After 48 hours in culture, cells 
displaying anoikis were not observed in zVAD treated 
cells. Western blot analysis showed dramatic reduction 
of cleaved PARP in F-CIC-R1515H zVAD treated cells 
(Figure 8D) compared to untreated cells and showed that 
pACLY levels were lower in these cells. These findings are 
compatible with the notion that reductions in pACLY led 
to anoikis and cell death. Increased caspase activity and 
reduced clonogenicity in cell lines expressing mutant IDH 
and the R1515H mutant CIC in vitro appears to mimic the 
slow growing nature of ODGs and may explain why it is 
difficult to grow ODGs with IDH1 and CIC mutations in 
vitro [30, 44, 45]. It is noteworthy that to date, no 1p19q 
co-deleted ODG cell lines with both IDH1 and CIC point 
mutations are available, despite 70% of ODGs carrying 
mutations in both genes.
DISCUSSION
Although CIC has been implicated in human 
diseases including cancers, the biology of CIC in 
mammalian cells remains poorly understood. Using 
immunoblotting and MRM mass spectrometry assays, we 
have confirmed the presence of two forms of endogenous 
CIC in HEK, oligodendroglioma (ODG) cells and tumour 
tissues (Figure 1, Figure 7). We further determined the 
subcellular localization of CIC-S (cytoplasm) and CIC-L 
(nucleus) in human cells. Localization of these isoforms to 
different compartments may indicate that these isoforms 
have distinct functions.
CIC was reported to be a transcriptional repressor 
in Drosophila nucleii and in mammalian cells [16, 17]. 
As far as we are aware, ours is the first study to report 
the localization of endogenous CIC-S and its proximity 
to mitochondria, the first study to report CIC-protein 
interactions and the first study to link CIC and mutations 
therein to roles in citrate metabolism. Cytosolic citrate is 
converted into 2KG by IDH1 and IDH1-R132H mediates 
the conversion of 2KG into 2HG, which accumulates at 
high levels in cells. ACLY on the other hand, converts 
cytosolic citrate into Acetyl-CoA that is essential for 
de novo lipid synthesis. In this paper, we established a 
possible mechanism of cooperative regulation of cytosolic 
citrate by mutant IDH1 and CIC.
Since IDH1 is the most frequently mutated gene in 
1p19q co-deleted ODG and CIC is mutated in ~70% of 
oligodendrogliomas, we studied the effects of expressing 
wild type and mutant CIC in combination with IDH1-
R132H on cell proliferation, cell survival and cell death 
using ODG cell culturing conditions. We for the first time 
showed a cooperative regulation of 2HG in mammalian 
cells expressing both mutant IDH1-R132H-V5 and the 
R1515H mutant CIC. Since high levels of 2HG can be 
toxic to cells [26], the cooperative increase in 2HG in the 
mutant cells expressing both IDH1-R132H-V5 and F-CIC-
R1515H may explain at least in part the cooperative 
reduction in clonogenicity in these stable cell lines under 
ODG culturing conditions. Among the somatic mutations 
observed in CIC in gliomas, 41% and 7% of all missense 
mutations were observed in the HMG binding domain and 
protein binding domain, respectively [2, 5, 7, 8]. Since 
HEK293 cells co-expressing IDH1-R132H-V5 with F-CIC 
or F-CIC-R201W produce less 2HG compared to the cells 
co-expressing IDH1-R132H-V5 and F-CIC-R1515H, 
it is tempting to speculate that in gliomas, missense 
mutations in the HMG domain alter its function to produce 
a 2HG level for tumour cells that balances cell survival 
and increased tumorogenicity, and for this reason such 
mutations are observed more frequently than missense 
mutations in the protein binding domains. In contrast 
to HEK293 cells, HOG-derived cells expressing IDH1-
R132H-V5 alone also showed elevated levels of 2HG and 
co-expression of IDH1-R132H-V5/ F-CIC significantly 
reduced the 2HG levels. Even so, co-expression of IDH1-
R132H-V5 and F-CIC-R1515H resulted in increased 
2HG compared to HOG cells co-expressing either wild 
type F-CIC or mutant F-CIC-R201W, consistent with the 
HEK results. HOG cells differ from HEK cells in several 
ways, and so this level of concordance is likely reflective 
of underlying biology, not technical artifact. 
The levels of ACLY/pACLY modulate 
tumourigenicity in gliomas [20]. Increased abundance of 
ACLY and pACLY was also associated with proliferation 
in other types of aggressive cancers [40, 42, 46–48]. 
In glioma cells, increased pACLY was observed in 
pseudopodia of U87 glioblastoma cells and was associated 
with increased clonogenicity and cell migration [20]. In 
other studies, inhibition or reduction of ACLY suppressed 
cell proliferation [38, 49, 50]. Consistent with these 
findings, we assigned a novel function to mutant CIC-S 
in reducing ACLY/pACLY levels in our cell lines and in 
human tumour samples and correlated this reduction with 
reduced clonogenicity in vitro. 
Whether mutations in IDH1 promote or inhibit 
cell proliferation and survival depends on the tumor 
site. While mutations in IDH genes in Acute Myeloid 
Leukemia have been associated with poor prognosis, the 
same mutations are considered as markers of improved 
prognosis in gliomas, indicating interactions with other 
proteins or the tumour environment may ultimately 
influence the role of IDH in tumour pathogenesis. While 
several studies of glioma patient samples [51, 52] found 
no correlation between IDH1 mutations and tumour 
invasiveness, another study [53] in a fibrosarcoma cell 
line with endogenous IDH1-R132C showed a requirement 
for mutant IDH1 protein for cell survival. Our study is 
in agreement with studies [54, 55] in glioma cell lines 
stably transfected with IDH1-R132H-V5, where reduced 
proliferation and cell migration in vitro and in vivo were 
reported. 
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Our study showed for the first time a cooperative 
reduction in clonogenicity in cells co-expressing IDH1-
R132H and mutant CIC proteins. A cooperative phenotype 
of lower proliferation driven by co-expression of mutant 
IDH1 and mutant CIC proteins in HEK293 and HOG 
stable cell lines is at least in part in agreement with 
several important observations in gliomas: (a) Glioma 
patients with IDH1-R132H or IDH2-R172K had slower 
tumour progression, longer survival and better response 
to radiation or Temozolomide treatment [55, 56]; (b) 
Mutations in CIC were almost always observed in 
1p19q co-deleted ODG and patients with this type of 
ODG had slower tumour growth and longer overall 
survival compared to ODG without co-deletion [2, 4]; 
(c) Transgenic mouse models expressing IDH1-R132H 
in brain exhibit hemorrhage, reduced proliferation and 
increased apoptosis and failed to spontaneously develop 
brain tumors [57]; (d) Attempts to culture ODG cells in 
vitro failed to grow ODG lines that harbor both IDH1 and 
CIC mutations [44, 58]. 
Although the reduced clonogenicity and cell 
proliferation of IDH1 and CIC mutations alone or in 
combination are in agreement with the slow growing 
nature of ODG with 1p19q co-deletions, the selective 
advantage that slow growth confers on malignant cells 
is unclear. One explanation may be that other oncogenic 
proteins or pathways may drive or be permissive for 
tumour progression of ODGs initially. In line with this 
hypothesis, a recent study by Killela and colleagues [9] 
identified recurrent mutations in the C228T or C250T 
positions of TERT promoters in ODGs with 1p19q 
deletions and suggested that these mutations may promote 
a self-renewal capability in these tumours. It is possible 
that the mutations in IDH1 and CIC may in fact be 
moderately deleterious and reduce clonogenicity but may 
provide other timely survival advantages under certain 
conditions during oligodendroglioma disease progression. 
MATERIALS AND METHODS
Cell culture, cell lysate preparations and western 
blot analysis
HEK293A, MDA-MB-231, HOG, and HeLa cell 
lines were cultured in DMEM (Invitrogen) supplemented 
with 10% (v/v) heat inactivated FBS (Invitrogen). C643 
and H522 cell lines were cultured in RPMI (Invitrogen) 
supplemented with 10% (v/v) heat inactivated FBS. 
Stable cell lines derived from HEK293A or HOG were 
cultured in DMEM+10% FBS with selection (G418 and 
zeocin). Unless otherwise indicated, experiments with 
stable cell lines were always performed between passages 
8-14. Cells were cultured without selection for at least 
two passages before experiments. Cell culturing was 
performed in a humidified, 37°C, 5% CO2 incubator. Cell 
lysate preparations, cell fractionations and western blot 
analysis were performed using standard protocols and are 
described in detail in the Supplementary data S1.
Immunoprecipitation, mass spectrometry and 
identification of candidate interaction partners
For CIC immunoprecipitation, myc-CIC-S or 
rabbit/mouse IgG (control) antibody-bound beads were 
prepared by incubating anti-CIC antibody, anti-myc 
antibody, normal rabbit-IgG, or mouse-IgG with protein 
G agarose beads (Roche) in IP buffer (20mM Tris-HCl 
pH 7.5, 150mM NaCl, 1mM EDTA with 1X complete 
protease inhibitor from Roche) at 4°C overnight. 
Cell lysates were first pre-cleared with Sepharose 4B 
beads (Sigma) at 4°C for 1 hour and the lysates were 
immunoprecipitated with the prepared protein-G beads 
at 4ºC for 4 hours. The captured proteins and protein 
complexes were released by boiling the beads in 2X LDS 
Sample Buffer (Invitrogen) at 95oC for 5 minutes or 2X 
SDS sample buffer (117mM Tris-Cl pH6.8, 4% SDS, 
8% glycerol, 0.01% bromophenol blue, 200mM DTT) at 
98oC for 10 minutes (see supplementary for details). For 
immunoprecipitations using FLAG epitopes, complexes in 
the pre-cleared lysate were captured by anti-FLAG M2 
Affinity agarose (Sigma) for 2 hours at 4°C. Captured 
proteins and complexes were eluted by two rounds of 
FLAG-peptide competition (400ug/mL FLAG peptide, 
50mM ammonium bicarbonate) for 30 minutes at 4°C. 
Serum free cell culturing
Cells were first plated in DMEM+10% FBS. The 
following day, media were replaced with Neurocult 
proliferation media supplemented with cytokines (Stem 
Cell Technologies) and growth factors EGF, FGF (20µg/
ml each; Peprotech) and Heparin (0.1%; Stem Cell 
Technologies) and cells were grown for the time periods 
indicated. For caspase inhibition assays, cells were grown 
with or without the pan caspase inhibitor zVAD-FMK (BD 
Biosciences)
Clonogenic and crystal violet cell proliferation 
assays
Stable cell lines were plated at 1x104 cells per well 
in a 6-well plate. Cells were grown in ODG media for up 
to 2weeks. Colonies were fixed with 4% paraformaldehyde 
and stained with 10% crystal violet. Images of colonies 
were captured using a Bio-Rad imaging system. Retained 
crystal violet stain was resolubilized in 1ml 10% acetic 
acid by rocking for 15 min. Readings were taken at A590 
using a plate reader (VersaMAX Microplate Reader). 
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Statistical analysis
For multiple comparisons of western blot 
results, 2HG/2KG levels and clonogenic crystal violet 
proliferation assays, one-way ANOVA with Dunnett’s 
post-test were performed using Prism 6.0 Software 
(GraphPad Software Inc.).
For further descriptions of Materials and Methods, 
please see the Supplementary Materials and Methods. 
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